Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study To Assess The Safety And Tolerability Of BEMA Buprenorphine NX In Opioid Dependent Subjects (BNX-201)

Trial Profile

An Open Label Study To Assess The Safety And Tolerability Of BEMA Buprenorphine NX In Opioid Dependent Subjects (BNX-201)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Buprenorphine/naloxone (Primary)
  • Indications Opioid abuse
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 16 Mar 2015 A sNDA submission is anticipated by the fourth quarter of 2015, according to a BioDelivery Sciences International media release.
    • 07 Aug 2013 Based on outcomes of this trial, and a bioequivalence trial, an NDA was submitted to the FDA for BUNAVAIL [buprenorphine/naloxone], according to a BioDelivery Sciences International media release issued on 1 August 2013.
    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top